MSF urges public and non-profit actors to publish clinical trial costs to improve access to medical products

endTB clinical trial offers new shortened drug regimens to treat multidrug-resistant TB

Governments must immediately implement latest WHO guidelines to stop children dying from TB

Recent price reductions to WHO-recommended TB tests and treatment should enable more countries to make these vital medical tools available

MSF welcomes Johnson & Johnson's intent not to enforce its patents on key TB drug bedaquiline, paving way for affordable generic versions

Governments must now turn words on paper into practice and take the necessary steps to save more lives of people with TB

Cepheid and Danaher have just announced that they are reducing the price of the Xpert MTB/RIF test by 20% in high-TB-burden countries, from US$9.98 to $7.97 per test. This reduction is a significant step, considering the corporations ...

MSF calls on J&J and Cepheid/Danaher to commit to improving access to key TB drug and test by UNHLM 22 September

MSF calls on Johnson & Johnson not to enforce its secondary patents on TB drug bedaquiline

MSF calls on J&J not to enforce secondary patents on TB drug bedaquiline, to improve global access to this lifesaving medicine

Access to TB drug bedaquiline, a backbone medicine for drug-resistant TB treatment regimens, remains out of reach for too many

2019 patent challenge by TB survivors, Nandita Venkatesan and Phumeza Tisile, was successful against J&J's secondary patent application for bedaquiline.

MSF called on governments and donors to speed up access to diagnostic tests, and shorter, safer and more effective treatments, for DR-TB.

Ahead of the final hearing on a patent challenge by two TB survivors, MSF urges the Indian Patent Office to reject Johnson & Johnson’s secondary patent application so that other manufacturers may enter the supply chain with more ...

Findings that prompted WHO to update global DR-TB treatment guidelines now published in the New England Journal of Medicine, show that a much shorter treatment regimen for drug-resistant TB is safer and cured almost 90 percent of ...

The World Health Organization’s Global Tuberculosis Report 2022 highlights that still only one in three people with drug-resistant tuberculosis is getting treatment, and the treatment success rate for those who do receive treatment ...

A MSF report released today finds that two newer TB drugs – bedaquiline and delamanid – going off patent in 2023 presents a critical opportunity to increase access to shorter, safer and better treatment for people with drug-resistant ...

MSF reiterates that the price of a full DR-TB treatment course should be no more than US$500 per person.

Delays in supply of the critical GeneXpert TB test are unacceptable. Now more than ever, we need a doubling down on urgent actions to help countries scale up lifesaving TB testing.

The World Health Organization (WHO) announced global treatment guidance with new, safer and more effective six-month oral treatment regimen for multidrug-resistant tuberculosis.